Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck, PMID: 32537431
Nimotuzumab: beyond the EGFR signaling cascade inhibition, PMID: 30318080
Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study, PMID: 30830679
Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma, PMID: 32426197
177Lu-nimotuzumab, PMID: 22817873
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer, PMID: 31150120
Nimotuzumab Site-Specifically Labeled with 89 Zr and 225 Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers, PMID: 33233524
90Y-DOTA-nimotuzumab: Synthesis of a Promising β⁻ radiopharmaceutical, PMID: 33397277
Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis, PMID: 30907986
Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma, PMID: 32319582
Nimotuzumab in pediatric glioma, PMID: 19903064
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer, PMID: 32064043
Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft, PMID: 30800216
Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study, PMID: 31888551
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin, PMID: 20046573
89 Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I, PMID: 29682209
Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China, PMID: 32494195
Profile of nimotuzumab in the treatment of high-grade glioma, PMID: 25926743
Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma, PMID: 33008416
Nimotuzumab treatment of malignant gliomas, PMID: 23043252
Preclinical Evaluation of 111 In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models, PMID: 30655327
Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line, PMID: 30854050
Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease, PMID: 30633365
Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature, PMID: 30417211
Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer, PMID: 31956621
A radiopharmaceutical [ 89 Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo, PMID: 30826708
Anti-EGFR therapies in nasopharyngeal carcinoma, PMID: 32836074
Nimotuzumab for pediatric diffuse intrinsic pontine gliomas, PMID: 21171927
Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177 Lu-Nimotuzumab, PMID: 32657634
EGFR-targeted therapies in the post-genomic era, PMID: 28866730
Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma, PMID: 32850421
Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer, PMID: 31353134
Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer, PMID: 31564975
Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma, PMID: 32973932
Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro, PMID: 29552167
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer, PMID: 28210119
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity, PMID: 19624281
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas], PMID: 21575527
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients, PMID: 28674498
Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [ 111 In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR, PMID: 31706737
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma, PMID: 29920955
Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study, PMID: 31069191
[Nimotuzumab significantly enhances chemosensitivity of PC9 human lung adenocarcinoma cells to paclitaxel in vitro], PMID: 25676404
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients, PMID: 24613543
Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3, PMID: 23232108
Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study, PMID: 30235761
Nimotuzumab Inhibits Cholangiocarcinoma Cell Metastasis via Suppression of the Epithelial-Mesenchymal Transition Process, PMID: 28668850
Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab, PMID: 18097777
Nimotuzumab plus chemotherapy with docetaxel, cisplatin, 5-fluorouracil for locally advanced head and neck squamous cell carcinoma: A clinical study, PMID: 30964103
Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study, PMID: 29285832
Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study., PMID:40526208
Survival outcomes and safety of nimotuzumab combined with radiotherapy ± chemotherapy for locally advanced cervical cancer., PMID:40450867
Identifying Molecular Probes for Fluorescence-Guided Surgery in Neuroblastoma: A Systematic Review., PMID:40426729
Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer: a multicenter real-world study., PMID:40335598
Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial., PMID:40325445
Erratum: Efficacy and Safety of Combined PD-1 Inhibitor with Induction Chemotherapy Followed by IMRT Plus Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Analysis [Corrigendum]., PMID:40296898
Correction: Predicting progression-free survival using dynamic contrast-enhanced imaging-based radiomics in advanced nasopharyngeal carcinoma patients treated with nimotuzumab., PMID:40227348
Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma., PMID:40215977
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer., PMID:40126545
Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment., PMID:40123590
Efficacy and Safety of Combined PD-1 Inhibitor With Induction Chemotherapy Followed by IMRT Plus Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Analysis., PMID:40017718
Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China., PMID:39984658
Predicting progression-free survival using dynamic contrast-enhanced imaging-based radiomics in advanced nasopharyngeal carcinoma patients treated with nimotuzumab., PMID:39953153
Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review., PMID:39941789
Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis., PMID:39896749
Efficacy and safety of molecular targeted therapies in nasopharyngeal carcinoma: a network meta-analysis., PMID:39838362
The inhibitory effects of nimotuzumab on CD276 expression and immune escape in head and neck squamous cell carcinoma: Insights into anticancer mechanisms., PMID:39778280
Nimotuzumab and bevacizumab combined with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme: a retrospective single-arm study., PMID:39760795
Neurobiology of COVID-19-Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling., PMID:39754403
The surgical safety margin after neoadjuvant chemotherapy combined with nimotuzumab leading to tumor regression., PMID:39710865
Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials., PMID:39637954
Efficacy and Safety of Neoadjuvant Immunotherapy Combined with Sandwich Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Study., PMID:39629196
Nimotuzumab and irinotecan synergistically induce ROS-mediated apoptosis by endoplasmic reticulum stress and mitochondrial-mediated pathway in cervical cancer., PMID:39624900
225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates., PMID:39603113
Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma., PMID:39526766
Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report., PMID:39512346
S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study., PMID:39462770
Successful treatment of GEMOX regimen combined with nimotuzumab in the pancreatic cancer with wild KRAS and mutant BRCA: a report of two cases., PMID:39380858
Efficacy and safety evaluation of first-line systemic treatments for unresectable esophageal squamous cell carcinoma: a network meta-analysis., PMID:39314629
Correction to "miR-199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1"., PMID:39297336
Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study., PMID:39183296
The addition of nimotuzumab during concurrent chemoradiotherapy improved survival outcomes in locally advanced nasopharyngeal carcinoma patients with optimal response to induction chemotherapy., PMID:39095737
Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review., PMID:39093329
Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II study., PMID:38988486
Unveiling the regulatory mechanism of nimotuzumab on PD-L1 expression in head and neck squamous cell carcinoma patients: Implications for enhanced anticancer treatment strategies., PMID:38977231
Epidermal growth factor receptor‑targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real-world study., PMID:38962426
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0., PMID:38958494
Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review., PMID:38950136
Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials., PMID:38939342
Combined Efficacy of Nimotuzumab and Gemcitabine on the Treatment of Advanced Pancreatic cancer., PMID:38888842
Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials., PMID:38873325
Nasopharyngeal carcinoma with leptomeningeal metastases has been treated with comprehensive treatment for long-term survival: A case report and literature review., PMID:38847717
Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial., PMID:38831450
Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma., PMID:38806289
A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma., PMID:38679408
Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma., PMID:38576484
Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis., PMID:38549541
Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma., PMID:38478066
A nanomedicine composed of polymer-ss-DOX and polymer-Ce6 prodrugs with monoclonal antibody targeting effect for anti-tumor chemo-photodynamic synergetic therapy., PMID:38460931
Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models., PMID:38360051
For research use only. Not for human or drug use.
